191 related articles for article (PubMed ID: 25740794)
1. Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.
Vanpouille C; Lisco A; Grivel JC; Bassit LC; Kauffman RC; Sanchez J; Schinazi RF; Lederman MM; Rodriguez B; Margolis L
Clin Infect Dis; 2015 Jun; 60(11):1708-14. PubMed ID: 25740794
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
3. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
[TBL] [Abstract][Full Text] [Related]
4. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
[TBL] [Abstract][Full Text] [Related]
5. Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Drake AL; Roxby AC; Ongecha-Owuor F; Kiarie J; John-Stewart G; Wald A; Richardson BA; Hitti J; Overbaugh J; Emery S; Farquhar C
J Infect Dis; 2012 Feb; 205(3):366-75. PubMed ID: 22147786
[TBL] [Abstract][Full Text] [Related]
6. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
Baeten JM; Strick LB; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
J Infect Dis; 2008 Dec; 198(12):1804-8. PubMed ID: 18928378
[TBL] [Abstract][Full Text] [Related]
8. HSV suppression reduces seminal HIV-1 levels in HIV-1/HSV-2 co-infected men who have sex with men.
Zuckerman RA; Lucchetti A; Whittington WL; Sánchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
AIDS; 2009 Feb; 23(4):479-83. PubMed ID: 19169140
[TBL] [Abstract][Full Text] [Related]
9. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
Nagot N; Ouédraogo A; Foulongne V; Konaté I; Weiss HA; Vergne L; Defer MC; Djagbaré D; Sanon A; Andonaba JB; Becquart P; Segondy M; Vallo R; Sawadogo A; Van de Perre P; Mayaud P;
N Engl J Med; 2007 Feb; 356(8):790-9. PubMed ID: 17314338
[TBL] [Abstract][Full Text] [Related]
10. Herpes Simplex Virus Suppressive Therapy in Herpes Simplex Virus-2/Human Immunodeficiency Virus-1 Coinfected Women Is Associated With Reduced Systemic CXCL10 But Not Genital Cytokines.
Andersen-Nissen E; Chang JT; Thomas KK; Adams D; Celum C; Sanchez J; Coombs RW; McElrath MJ; Baeten JM
Sex Transm Dis; 2016 Dec; 43(12):761-764. PubMed ID: 27832025
[TBL] [Abstract][Full Text] [Related]
11. Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
Roxby AC; Drake AL; Ongecha-Owuor F; Kiarie JN; Richardson B; Matemo DN; Overbaugh J; Emery S; John-Stewart GC; Wald A; Farquhar C
PLoS One; 2012; 7(6):e38622. PubMed ID: 22701683
[TBL] [Abstract][Full Text] [Related]
12. The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
Van Wagoner N; Geisler WM; Bachmann LH; Hook EW
Int J STD AIDS; 2015 Jul; 26(8):574-81. PubMed ID: 25147236
[TBL] [Abstract][Full Text] [Related]
13. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.
Ouedraogo A; Nagot N; Vergne L; Konate I; Weiss HA; Defer MC; Foulongne V; Sanon A; Andonaba JB; Segondy M; Mayaud P; Van de Perre P
AIDS; 2006 Nov; 20(18):2305-13. PubMed ID: 17117016
[TBL] [Abstract][Full Text] [Related]
14. Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized, placebo-controlled crossover trial.
Yi TJ; Shannon B; Chieza L; Su D; Saunders M; Tharao W; Huibner S; Remis R; Raboud J; Kaul R
J Infect Dis; 2014 Sep; 210(5):708-12. PubMed ID: 24664172
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
Baeten JM; Lingappa J; Beck I; Frenkel LM; Pepper G; Celum C; Wald A; Fife KH; Were E; Mugo N; Sanchez J; Essex M; Makhema J; Kiarie J; Farquhar C; Corey L
J Infect Dis; 2011 Jan; 203(1):117-21. PubMed ID: 21148504
[TBL] [Abstract][Full Text] [Related]
16. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression.
Schacker T; Zeh J; Hu H; Shaughnessy M; Corey L
J Infect Dis; 2002 Dec; 186(12):1718-25. PubMed ID: 12447756
[TBL] [Abstract][Full Text] [Related]
17. The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial.
Rasmussen TA; McMahon JH; Chang JJ; Audsley J; Rhodes A; Tennakoon S; Dantanarayana A; Spelman T; Schmidt T; Kent SJ; Morcilla V; Palmer S; Elliott JH; Lewin SR
Lancet HIV; 2018 May; 5(5):e221-e230. PubMed ID: 29643011
[TBL] [Abstract][Full Text] [Related]
18. The effect of daily valacyclovir suppression on herpes simplex virus type 2 viral shedding in HSV-2 seropositive subjects without a history of genital herpes.
Sperling RS; Fife KH; Warren TJ; Dix LP; Brennan CA
Sex Transm Dis; 2008 Mar; 35(3):286-90. PubMed ID: 18157071
[TBL] [Abstract][Full Text] [Related]
19. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.
Reynolds SJ; Makumbi F; Newell K; Kiwanuka N; Ssebbowa P; Mondo G; Boaz I; Wawer MJ; Gray RH; Serwadda D; Quinn TC
Lancet Infect Dis; 2012 Jun; 12(6):441-8. PubMed ID: 22433279
[TBL] [Abstract][Full Text] [Related]
20. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.
Dunne EF; Whitehead S; Sternberg M; Thepamnuay S; Leelawiwat W; McNicholl JM; Sumanapun S; Tappero JW; Siriprapasiri T; Markowitz L
J Acquir Immune Defic Syndr; 2008 Sep; 49(1):77-83. PubMed ID: 18667923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
